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Blocking drug activation as a 
therapeutic strategy to attenuate 
acute toxicity and physiological 
effects of heroin
Ting Zhang1,2, Xirong Zheng1,2, Kyungbo Kim1,2, Fang Zheng1,2 & Chang-Guo Zhan1,2
Heroin is a growing national crisis in America. There is an increasing frequency of heroin overdoses. All of 
the currently used therapeutic approaches to treatment of heroin abuse and other opioid drugs of abuse 
focus on antagonizing a brain receptor (particularly µ-opiate receptors). However, it has been known 
that the therapeutic use of certain µ-opiate receptor antagonist may actually increase heroin overdose. 
Once overdosed, heroin addicts may continue to get overdosed again and again until fatal. Here we 
report our design and validation of a novel therapeutic strategy targeting heroin activation based on 
our analysis of the chemical transformation and functional change of heroin in the body. An effective 
blocker of heroin activation, such as ethopropazine tested in this study, may be used as a standalone 
therapy or in combination with a currently available, traditional medications targeting µ-opiate 
receptors (e.g. naltrexone or its extended-release formulation Vivitrol). The combination therapy would 
be ideal for heroin abuse treatment as the effects of two therapeutic agents targeting two independent 
mechanisms are cooperative.
Heroin is known as a growing national crisis in America, due to the rapidly increasing overdose deaths. From 
2001 to 2014, heroin overdose deaths nationwide increased 594 percent and continued to dramatically increase 
since 2014, according to the Centers for Disease Control (https://www.cdc.gov/drugoverdose/epidemic/index.
html), and “heroin is scarring the next generation”1. The connection between heroin abuse and prescription opioid 
abuse is related to the actual availability, in addition to the common brain protein target (µ-opiate receptors), 
of these opioid drugs. In fact, “80% of recent heroin initiates reported that they began their opioid use through the 
nonmedical use of prescription opioid medications”2. The prevalence of prescription opioid abuse is similar among 
men and women. Those who abuse the prescription drugs most often obtain them from friends and family either 
through sharing or theft. When they are no longer able to get prescription opioid drugs, they start to use illegal 
opioid heroin, because heroin is easy to obtain on the street and even online. In addition, heroin has become 
much cheaper than any other drug of abuse, e.g. $10–$20 for a typical single dose (0.1 g) of heroin purchased on 
the street2. Due to the connection between heroin abuse and prescription opioid abuse, further enhancing law 
enforcement through improving existing prescription drug monitoring programs3 might effectively reduce the 
prescription opioid abuse. On the flip side, the reduced prescription opioid abuse could lead to increase of the 
heroin abuse. As a result, the overall opioid overdose deaths might not really decrease. For example, study showed 
prescription drug abuse declining in Kentucky4, due to the strict Kentucky All Schedule Prescription Electronic 
Reporting Program (KASPER). Unfortunately, the heroin overdose has dramatically increased4, and the total 
number of drug overdose deaths actually went up in Kentucky2,5. So, further enhancing law enforcement through 
improving prescription drug monitoring programs should be associated with development of a more effective 
therapeutic strategy for heroin abuse.
Currently used therapeutic agents for treatment of heroin abuse and other opioid drugs of abuse include 
naloxone for overdose treatment and buprenorphine, methadone, and naltrexone for addiction treatment. These 
therapeutic agents may be used in various formulations/devices, such as nasal spray device for naloxone6 for fast 
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overdose treatment and extended-release naltrexone for relapse-preventing addiction treatment7. All of these 
therapeutic agents in the current clinical use, and other therapeutic candidates under preclinical/clinical develop-
ment, bind to µ-opiate receptors (and/or a related receptors) in the brain and, thus, block the physiological effects 
of heroin or another opioid used. The overdose treatment with naloxone appears to be effective, but the precon-
dition is that the naloxone treatment can begin soon enough after a heroin overdose. For the problem, once over-
dosed, heroin addicts may continue to get overdosed again and again until fatal. Some heroin addicts survived 
from one overdose with treatment in hospital, and then died of another overdose the next day2. Even worse, the 
use of naltrexone or its extended-release formulation Vivitrol actually increased heroin overdose8–10. A truly effective 
heroin treatment should account for not only rescuing heroin addicts who have already been overdosed, but also 
preventing the addicts from overdose again.
Here we report our mechanism-based rational design and validation of a novel therapeutic strategy targeting 
heroin activation to complement the currently available antagonist approach. Our strategy is based on the fact 
that heroin itself is actually a prodrug which must be activated to be effective, and our further analysis of the 
chemical transformation and functional change of heroin in the body. An effective blocker of heroin activation 
may be used as a standalone therapy or in combination with one of the currently available traditional medications 
targeting µ-opiate receptors (e.g. naltrexone or its extended-release formulation Vivitrol). The combination ther-
apy would be ideal for heroin abuse treatment as the effects of two therapeutic agents targeting two independent 
mechanisms are perfectly cooperative.
Results
Catalytic parameters of the primary enzyme involved in heroin activation. It has been known 
that heroin (3,6-diacetylmorphine, synthesized from morphine) behaves as a prodrug and its effects are medi-
ated by its metabolites (6-MAM and morphine depicted in Fig. 1)11,12. Once administered, heroin is very rapidly 
metabolized by cholinesterases to 6-monoacetylmorphine (6-MAM) first, and then to morphine (see Fig. 1). Both 
6-MAM and morphine are responsible for the toxic and physiological effects of heroin13–20. In fact, heroin is at 
least 10-fold more toxic than morphine16, but the binding affinity of heroin itself with the µ-opiate receptors is 
significantly lower than that of morphine. The most toxic metabolite is 6-monoacetylmorphine (6-MAM) which 
has the highest binding affinity with the µ-opiate receptors. 6-MAM (with a relatively shorter biological half-life 
compared to morphine) is mainly responsible for the acute toxicity17, whereas morphine (with a much longer bio-
logical half-life) is mainly responsible for the long-term toxicity, of heroin. So, cholinesterases are crucial enzymes 
that control the metabolic profile, and thus affect the toxic and physiological effects, of heroin.
There are two main cholinesterases, including acetylcholinesterase (AChE) and butyrylcholinesterase (BChE). 
Which cholinesterase (AChE or BChE) is mainly responsible for heroin hydrolysis has been controversial. It was 
once proposed that human erythrocyte AChE is responsible for hydrolyzing heroin21. However, further studies by 
Lockridge et al. indicated that human serum BChE, instead of erythrocyte AChE, is responsible for hydrolyzing 
heroin13. As previously reported catalytic parameters for BChE-catalyzed hydrolysis of heroin were inconsistent 
(kcat = 12.5 to 540 min−1 and KM = 110 to 3500 µM)13,22,23, we performed the Michaelis-Menten kinetic analysis of 
the BChE-catalyzed hydrolysis of heroin at 37 °C. The kinetic data (Fig. 2A) reveal that recombinant human BChE 
is highly efficient for heroin hydrolysis (kcat = 1840 min−1 and KM = 120 µM), which is qualitatively consistent with 
the conclusion obtained by Lockridge et al.13. According to reported pharmacokinetic studies17, heroin is con-
verted to 6-MAM with a very high metabolic rate in blood (with a rate constant for heroin hydrolysis to 6-MAM 
as high as 12.092 min−1), and the estimated metabolic rate of heroin in brain was much lower. The very different 
metabolic rates for heroin in blood and brain calculated by the model were confirmed by in vitro experiments18, 
which also supports the notion that BChE (which is the dominant cholinesterase in serum) is the primary enzyme 
responsible for heroin activation. Further, heroin is either eliminated very rapidly from the body (by some direct 
pathway, e.g. urine) or metabolized rapidly to 6-MAM in plasma, according to the well-established pharmacoki-
netic (PK) model (the rate constant is 13.757 min−1 for direct heroin elimination and 12.092 min−1 for heroin 
hydrolysis to 6-MAM)18. Therefore, we propose to target heroin activation by using a BChE-selective inhibitor in 
order to attenuate the toxic and physiological effects of heroin. When the metabolic pathway of heroin by BChE is 
blocked, heroin will mainly go through the direct elimination process to urine. Hence, blocking BChE-catalyzed 
hydrolysis of heroin should help to significantly attenuate the actual toxicity and physiological effects of heroin.
Effects of ethopropazine on heroin-induced hyperactivity. Notably, many cholinesterase inhibitors 
have been approved by the FDA as therapeutic agents for treatment of Alzheimer’s disease (AD), myasthenia 
gravis, glaucoma, and Parkinson’s disease etc. Most of these cholinesterase inhibitors are able to inhibit both 
AChE and BChE, without the desirable high selectivity for BChE over AChE. Nevertheless, ethopropazine (a 
BChE inhibitor approved by the FDA for treatment of Parkinson’s disease) is highly selective for BChE over 
Figure 1. The metabolic pathway of heroin to morphine – hydrolysis reactions catalyzed by cholinesterases.
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AChE, with IC50 = 210–300 nM for BChE and IC50 = 210 μM for AChE (~1000-fold selectivity)24. So, ethopro-
pazine was used to examine whether a BChE-selective inhibitor can really attenuate the toxic and physiological 
effects of heroin in mice. First, we determined the effects of ethopropazine on heroin-induced hyperactivity by 
performing locomotor activity tests in high density, non-porous plastic chambers measuring 50 cm (L) × 50 cm 
(W) × 38 cm (H) in a light- and sound-attenuating behavioral test enclosure (San Diego Instruments, San Diego, 
CA). As seen in Fig. 2, ethopropazine (10 mg/kg, IV) administration 10 min prior to the heroin (2.5 mg/kg, IP) 
injection significantly attenuated heroin-induced hyperactivity.
Effects of ethopropazine on heroin-induced acute toxicity. Ethopropazine was tested further for its 
effectiveness in protecting mice against heroin-induced acute toxicity. Heroin-induced acute toxicity was char-
acterized by the lethality (occurrence of death). For the protection experiments, a single dose of ethopropazine 
was administrated (IV) prior to administration of a lethal dose (LD100) of heroin (e.g. 25 mg/kg, IV). At 10 min 
after IV administration of ethopropazine or saline (negative control), the mice were given a lethal dose (LD100) 
of heroin. The protection experiments were performed under various dose conditions (n = 6 for each scenario). 
Depicted in Fig. 3 are the data obtained from the protection experiments with ethopropazine (1 or 10 mg/kg, IV) 
and/or naltrexone (0.3 mg/kg, IV); we also tried to use a higher dose (1 mg/kg, IV) of naltrexone and noted that 
the IV dose of 1 mg/kg would be too high because the mice injected intravenously with 1 mg/kg naltrexone were 
not able to stand and could hardly move at all.
The data depicted in Fig. 3 reveal that, without ethopropazine or naltrexone administration, all mice died 
within 2 min after the heroin injection (25 mg/kg, IV). However, pre-treatment of mice with ethopropazine 
(10 mg/kg, IV) 10 min before the heroin injection protected all mice against the acute toxicity of a lethal dose of 
Figure 2. (A) Plot of measured initial reaction rates (represented in nM min−1 per nM enzyme, or min−1, at 
37 °C, measured in triplicate, with error bars in standard deviations) versus the substrate (heroin) concentration 
for recombinant human BChE-catalyzed hydrolysis of heroin. (B) Locomotor activity in mice expressed as 
total distance traveled (in centimeters) per min after heroin injection (2.5 mg/kg, IP) or saline, with or without 
ethopropazine injection (10 mg/kg, IV) 10 min prior to the heroin (or nothing) injection (2.5 mg/kg, IP) at the 
time 0. A group of eight mice (n = 8) were used at the same time for each dose condition.
www.nature.com/scientificreports/
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heroin (25 mg/kg, IV). So, 10 mg/kg ethopropazine was able to protect all of the mice from the heroin-induced 
lethality (full protection).
Further, we also tested whether Galantamine (a highly potent and selective inhibitor of AChE, approved 
by the FDA for treatment of Alzheimer’s disease) can also attenuate heroin-induced toxicity, and found that 
pre-treatment of mice with Galantamine at a dose of 10 or 5 mg/kg (IV or IP) before the heroin injection did not 
protect any mouse against the acute toxicity of a lethal dose of heroin (25 mg/kg, IV), which is consistent with the 
concept that BChE, rather than AChE, is the primary heroin-activating enzyme.
Additional data in Fig. 3 indicate that 1 mg/kg ethopropazine or 0.3 mg/kg naltrexone only provided partial 
protection, but the combined use of 0.3 mg/kg naltrexone and 1 mg/kg ethopropazine provided the full protec-
tion. So, the protection effects of ethopropazine and naltrexone are indeed cooperative, as expected.
Discussion
All of the animal data obtained consistently support the concept of using a potent BChE-selective inhibitor, such 
as ethopropazine tested in this study, as a blocker of heroin activation to attenuate the toxicity and physiological 
effects of heroin. For this reason, ethopropazine may be repurposed for clinical use to attenuate the acute toxicity 
of heroin.
Further, although a heroin activation blocker, such as ethopropazine which we have identified in this study for 
the first time, may be used as a standalone therapy for heroin addiction treatment, the combined use of a heroin 
activation blocker and a μ-opiate receptor antagonist should be more effective. This is because the two mecha-
nisms are independent and, therefore, their effects can be perfectly cooperative (Bliss Independence model)25,26. 
The cooperative effects of the two therapeutic agents should be much more effective. For example, if a heroin 
activation blocker with a given concentration in plasma can block heroin activation by 90% and if the μ-opiate 
receptor antagonist with a given concentration in the brain can block the receptors binding with the available 
active heroin metabolites (associated with 10% of the total heroin) also by 90%, then only 10% of the 10% (i.e. 
1% of the total) can bind with μ-opiate receptors. Thus, the two types of therapeutic agents together can block the 
toxicity and physiological effects of heroin by 99%, when each one can block the toxicity and physiological effects 
of heroin by 90%. For the same logics, the two types of therapeutic agents together can block the toxicity and 
physiological effects of heroin by 75%, when each one can block them by 50%; the two types of therapeutic agents 
together can block the toxicity and physiological effects of heroin by 99.99%, when each one can block them by 
99%. So, the novel combination therapy is potentially more promising for heroin addiction treatment and for 
prevention of heroin overdose. In addition, the general concept of a combination therapy with two therapeutic 
agents (e.g. ethopropazine combined with naltrexone or its extended-release formulation Vivitrol) targeting two 
independent mechanisms may also be useful for therapeutic treatment of other drugs of abuse.
Materials and Methods
Materials. The purified recombinant human BChE protein was prepared in our previous study27. Briefly, the 
BChE protein was expressed in CHO-S cells, and the secreted enzyme in the culture medium was purified by a 
two-step approach, including ion exchange chromatography using QFF anion exchanger and affinity chroma-
tography using procainamide-sepharose. The purified protein was stored at −80 °C before the use. Heroin and 
its metabolite 6-MAM were provided by the National Institute on Drug Abuse (NIDA) Drug Supply Program 
(Bethesda, MD). All other supplies (including ethopropazine and naltrexone) were purchased from Sigma-
Aldrich (St. Louis, MO).
Animals. Male CD-1 mice (28–32 g) were ordered from Harlan (Harlan, Indianapolis, IN), and housed in 
cage. All mice were allowed ad libitum access to food and water and maintained on a 12 h light/12 h dark cycle, 
with the lights on at 8:00 a.m. at a room temperature of 21–22 oC. Experiments were performed in a same colony 
room in accordance with the Guide for the Care and Use of Laboratory Animals as adopted and promulgated by 
the National Institutes of Health. The animal protocol was approved by the IACUC (Institutional Animal Care 
and Use Committee) at the University of Kentucky.
Figure 3. Effectiveness of ethopropazine (ET) and naltrexone in protection of mice against the acute toxicity 
of a lethal dose of heroin (25 mg/kg, IV). ET and/or naltrexone (IV) was administered (IV) 10 min before the 
heroin administration, in comparison with the control group (saline) without ET or naltrexone administration. 
Each data point represents the percentage of mice (n = 6 for each dose condition) exhibiting heroin-induced 
lethality.
www.nature.com/scientificreports/
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In vitro enzyme activity assay. For kinetic analysis of the catalytic activity of BChE against heroin, the 
purified enzyme and heroin were incubated in 0.1 M phosphate buffer, pH 7.4, at 37 °C. The enzymatic reaction 
was terminated and the protein was precipitated by adding 100 µl of iced 50% acetonitrile/0.5 M hydrochloric 
acid, followed by 5 min centrifugation at 15,000 g. The resulting supernatant was subjected to reverse-phase HPLC 
(RP-HPLC) on a 5 µm C18 110 Å column (250 × 4.6 mm; Gemini) and RP-HPLC was performed using the mobile 
phase consisting of 20% acetonitrile in 0.1% TFA. The remaining substrate (heroin) and the formed reaction 
product (6-MAM) were monitored by a fluorescence detector with an excitation wavelength of 230 nm and emis-
sion wavelength of 315 nm and by monitoring UV absorbance at 230 nm. The quantification was based on a 
standard curve prepared using an authentic standard compound. The measurement was performed in triplicate, 
and the catalytic parameters were determined by using the Michaelis-Menten kinetic equation.
Locomotor activity assay. To determine the effects of ethopropazine on heroin-induced hyperactiv-
ity, locomotor activity tests were performed in high density, non-porous plastic chambers measuring 50 cm 
(L) × 50 cm (W) × 38 cm (H) in a light- and sound-attenuating behavioral test enclosure (San Diego Instruments, 
San Diego, CA). This system available in our lab can test 8 mice at the same time. Cumulative distance traveled 
and speed were recorded by EthoVision XT video tracking system (Noldus Information Technology, Wageningen, 
Netherlands) to represent the locomotor activity. Mice were introduced to the test chambers for one habituation 
session (no injection). Before the test session, mice were allowed to acclimate to the test chambers for at least 
60 minutes, and the total distance traveled during this period of time were determine the basal activity. Then, 
ethopropazine or saline (negative control) was administered through intravenous (IV) injection. At 10 min after 
the ethopropazine or saline injection, the mice were given a pharmacological dose of heroin (e.g., 2.5 mg/kg, IP). 
After the heroin administration, mice were immediately returned to the test chamber for a 60-minute session of 
activity monitoring.
Protection study in mice. Heroin-induced acute toxicity was characterized in this study by the occurrence 
of death. Protection experiment was performed by pretreatment of mice with ethopropazine (1 or 10 mg/kg, 
IV) and/or naltrexone (0.3 mg/kg) 10 min before administration of heroin (25 mg/kg, IV). Following the heroin 
administration, mice were immediately placed in containers for observation. The presence or absence of death 
was recorded for 6 hours following heroin administration.
References
 1. Drash, W. & Blau, M. CNN Front Page News - In America's drug death capital: How heroin is scarring the next generation, (http://
www.cnn.com/2016/09/16/health/huntington-heroin/index.html) 5:45 PM ET, Fri., September 16, 2016 (last seen: December 2017).
 2. USDOJ. CD No. 2 (“1. Chasing the Dragon; 2. Heroin Hurts; 3. Heroin is Hell; 4. Heroin is Here; 5 Heroin’s Hold”), distributed to 
the invited attendees of US Attorney-General Loretta E. Lynch’s “National Heroin & Opioid Awareness Week” policy speech at 
College of Pharmacy, University of Kentucky on September 20, 2016 (2016).
 3. ONDCP. Prescription Drug Monitoring Programs, (https://obamawhitehouse.archives.gov/sites/default/files/ondcp/Fact_Sheets/
pdmp_fact_sheet_4-8-11.pdf) April 2011 (last seen: December 2017) (2011).
 4. WLKY. Study shows prescription drug abuse declining in Kentucky, (http://www.wlky.com/news/study-shows-prescription-drug-
abuse-declining-in-kentucky/34380884), and the comments on the report. 4:31 PM EDT Jul 27, 2015 (last seen: December 2017) 
(2015).
 5. USDOJ. CD No.1 (“CD of Heroin Facts and Other Documents”), distributed to the invited attendees of US Attorney-General Loretta 
E. Lynch’s “National Heroin & Opioid Awareness Week” policy speech at College of Pharmacy, University of Kentucky on September 
20, 2016 (2016).
 6. Krieter, P. et al. Pharmacokinetic Properties and Human Use Characteristics of an FDA-Approved Intranasal Naloxone Product for 
the Treatment of Opioid Overdose. J. Clin. Pharmacol. 56, 1243–1253 (2016).
 7. Zaaijer, E. R., Goudriaan, A. E., Koeter, M. W., Booij, J. & van den Brink, W. Acceptability of Extended-Release Naltrexone by 
Heroin-Dependent Patients and Addiction Treatment Providers in the Netherlands. Subst. Use Misuse 51, 1905–1911 (2016).
 8. Ritter, A. J. Naltrexone in the treatment of heroin dependence: relationship with depression and risk of overdose. Australian and New 
Zealand Journal of Psychiatry 36, 224–228 (2002).
 9. SAMHSA. The Facts about Naltrexone for Treatment of Opioid Addiction, (http://store.samhsa.gov/shin/content//SMA12-4444/
SMA12-4444.pdf), HHS Publication No. (SMA) I2-4444 (2012).
 10. Gibson, A. & Degenhardt, L. Mortality related to naltrexone in the treatment of opioid dependence: A comparative analysis, (https://
ndarc.med.unsw.edu.au/resource/mortality-related-naltrexone-treatment-opioid-dependence-comparative-analysis) NDARC 
Technical Report No. 229 (2005).
 11. Inturrisi, C. E. et al. Evidence from opiate binding studies that heroin acts through its metabolites. Life Sci. 33(Suppl. 1), 773–776 
(1983).
 12. Strandberg, J. J. et al. Toxicological analysis in rats subjected to heroin and morphine overdose. Toxicol. Lett. 166, 11–18 (2006).
 13. Lockridge, O., Mattershaw-Jackson, N., Eckerson, H. W. & LaDu, B. N. Hydrolysis of diacetylmorphine (heroin) by human serum 
cholinesterase. J. Pharmacol. Exp. Ther. 215, 1–8 (1980).
 14. Eddy, N. B. & Howes, H. A. Studies of morphine, codeine and their derivatives VIII Monoacetyl- and diacetylmorphine their 
hydrogenated derivatives. J. Pharmacol. Exp. Ther. 53, 430–439 (1935).
 15. Wright, C. I. & Barbour, F. A. The respiratory effects of morphine, codeine and related substances IV. The effect of alpha-
monoacetylmorphine, monoacetyldihydromorphine, diacetylmorphine (heroin) and diacetyldihydromorphine on the respiratory 
activity of the rabbit. J. Pharmacol. Exp. Ther. 54, 25–33 (1935).
 16. Selley, D. E. et al. mu-Opioid receptor-mediated G-protein activation by heroin metabolites: evidence for greater efficacy of 
6-monoacetylmorphine compared with morphine. Biochem. Pharmacol. 62, 447–455 (2001).
 17. Andersen, J. M., Ripel, A., Boix, F., Normann, P. T. & Morland, J. Increased locomotor activity induced by heroin in mice: 
pharmacokinetic demonstration of heroin acting as a pro-drug for the mediator, 6-monoacetylmorphine, in vivo. J. Pharmacol. Exp. 
Ther. 331, 153–161 (2009).
 18. Boix, F., Andersen, J. M. & Mørland, J. Pharmacokinetic modeling of subcutaneous heroin and its metabolites in blood and brain of 
mice. Addict. Biol. 18, 1–7 (2013).
 19. NIDA. DrugFacts: Heroin, (http://www.drugabuse.gov/publications/drugfacts/heroin) (2015).
 20. Wikipedia, http://en.wikipedia.org/wiki/Morphine#cite_note-urlDrugFacts:_Heroin_.7C_National_Institute_on_Drug_
Abuse_.28NIDA.29-23 (last seen: March 6, 2018) (2018).
www.nature.com/scientificreports/
6Scientific REPORTs |         (2018) 8:16762  | DOI:10.1038/s41598-018-35196-8
 21. Smith, D. A. & Cole, W. J. Identification of an arylesterase as the enzyme hydrolysing diacetylmorphine (heroin) in human plasma. 
Biochem. Pharmacol. 25, 367–370 (1976).
 22. Salmon, A. Y., Goren, Z., Avissar, Y. & Soreq, H. Human erythrocyte but not brain acetylcholinesterase hydrolyses heroin to 
morphine. Clinical and Experimental Pharmacology and Physiology 26, 596–600 (1999).
 23. Kamendulis, L. M., Brzezinski, M. R., Pindel, E. V., Bosron, W. F. & Dean, R. A. Metabolism of cocaine and heroin is catalyzed by the 
same human liver carboxylesterases. Journal of Pharmacology and Experimental Therapeutics 279, 713–717 (1996).
 24. Atack, O. A., Vu, Q.-S., Soncrant, T. T., Brossi, A. & Rapoport, S. I. Comparative Inhibitory Effects of Various Physostigmine Analogs 
against Acetyl- and Butyryicholinesterases. J. Pharm. Exp. Therap. 249, 194–202 (1989).
 25. Bliss, C. I. The calculation of microbial assays. Bacteriol. Rev. 20, 243–258 (1956).
 26. Bliss, C. I. The toxicity of poisons applied jointly. Ann. Appl. Biol. 26, 585–615 (1939).
 27. Chen, X. et al. Kinetic characterization of a cocaine hydrolase engineered from mouse butyrylcholinesterase. Biochem. J. 466, 
243–251 (2015).
Acknowledgements
This work was supported in part by the National Institutes of Health (NIH grants UH2/UH3 DA041115, R01 
DA035552, R01 DA032910, R01 DA013930, and R01 DA025100).
Author Contributions
T.Z. and X.Z. performed in vivo studies and analyzed the data. K.K. carried out the in vitro assay. F.Z. and C.-G.Z. 
designed the study, analyzed the data, and finalized the manuscript.
Additional Information
Competing Interests: The authors declare no competing interests.
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Cre-
ative Commons license, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons license and your intended use is not per-
mitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the 
copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
 
© The Author(s) 2018
